TL;DR: The most commonly cited epithalon dosing and cycle pattern in the research-education community is roughly 10 mg per day for 10 consecutive days (about a 100 mg course), repeated once or twice a year. Cell and animal studies show telomerase activation and pineal-melatonin effects, but robust modern human trials are lacking.
Epithalon — also written Epitalon or AEDG (Ala-Glu-Asp-Gly) — is a synthetic pineal tetrapeptide that keeps resurfacing in longevity forums with the same two questions attached: what is the actual protocol, and does any of it hold up? This article walks through the popular cycle, what the literature demonstrates, and where the evidence gets thin. For background on the molecule itself, see our primer on what Epithalon is and how the pineal tetrapeptide works. Everything below is for research and educational purposes only.
The Commonly Cited 10-Day Epithalon Protocol
The “10-day cycle” is the signature pattern people mean when they discuss epithalon dosing and cycle design. In its most-repeated form it looks like this:
- Daily research dose: typically cited in the 5–10 mg range
- Cycle length: 10 consecutive days
- Total course: roughly 50–100 mg per cycle
- Frequency: repeated once or twice per year (often described as a semi-annual “longevity cycle”)
- Route in the literature: subcutaneous administration is standard in the source studies
An important honesty note up front: this exact 10mg-for-10-days schedule is a community and clinic convention, not a number handed down from a large controlled human trial. It borrows the structure of the original Russian “course” dosing — short, intermittent bursts rather than continuous daily use — and pairs it with a round 10 mg figure that is convenient for a standard 10 mg vial. The underlying idea is that telomerase activation is a switch you flip periodically, so chronic daily exposure is considered unnecessary.
If you are reconstituting a vial to understand these figures on paper, our peptide reconstitution and dosing calculator converts vial size, bacteriostatic water volume, and target dose into draw amounts, and the 10 mg Epithalon reference page covers the format most protocols are written around.
Why 10 days on, then a long break?
The intermittent design traces back to how Vladimir Khavinson’s group ran their “peptide bioregulator” courses: short treatment windows spaced months apart, sometimes repeated over years. The rationale is mechanistic rather than proven-optimal — brief pulses are hypothesized to be enough to up-regulate telomerase and nudge the pineal melatonin rhythm, without the theoretical concerns that come with continuous stimulation of cell division. Nobody has published a modern dose-ranging trial comparing, say, 5 mg vs 10 mg or 10 days vs 20, so the “best” numbers remain an educated convention.
- 1
Days 1-10
Active course: ~5-10 mg subcutaneous per day, totaling roughly 50-100 mg.
- 2
Long off period
Months of no dosing — the pulse is hypothesized to be enough to flip the telomerase switch.
- 3
Repeat semi-annually
Course repeated once or twice per year, mirroring the original Russian 'course' pattern.
What the Research Actually Shows
Here is where the epithalon dosing and cycle conversation needs a reality check. The evidence base is real but lopsided: strong on cell-culture and rodent work, thin and dated on modern human trials.
Telomerase and telomeres (cell studies)
The foundational finding is from Khavinson, Bondarev, and Butyugov (2003), who reported that adding epithalon to human fetal fibroblast cultures induced expression of the telomerase catalytic subunit (hTERT), boosted enzyme activity, and elongated telomeres. A companion 2004 paper showed treated cells pushing past the normal Hayflick replicative ceiling — roughly 10 extra population doublings versus controls. These are the studies almost every marketing page paraphrases.
Crucially, this was replicated and extended in 2025: Al-dulaimi and colleagues, publishing in Biogerontology, found epitalon produced dose-dependent telomere lengthening in normal human cell lines via hTERT/telomerase up-regulation — and, notably, telomere extension in breast-cancer cell lines through the ALT (alternative lengthening of telomeres) pathway. That independent replication is genuinely useful, but note the caveat baked into it (more on cancer below).
Lifespan and tumors (animal studies)
Anisimov, Khavinson, and colleagues (2003) reported that epitalon given to female SHR mice improved several aging biomarkers and reduced spontaneous tumor incidence. Across Khavinson’s broader rodent program, lifespan extensions in the range of roughly 15–30% have been described. These are the most provocative numbers in the field — and also the ones most in need of independent Western replication, which remains sparse.
Pineal, melatonin, and sleep (human-adjacent work)
The pineal/sleep story rests largely on Korkushko and Khavinson’s work on melatonin rhythms. In aging monkeys and elderly people, pineal peptide preparations were reported to restore the nighttime melatonin peak and normalize its circadian amplitude. This is the mechanistic basis for the anecdotal “deeper sleep and vivid dreams” reports — but controlled, blinded sleep trials on epithalon specifically have not been published.
Evidence at a glance
| Claimed effect | Strongest evidence | Evidence stage | Independent replication |
|---|---|---|---|
| Telomerase activation / telomere lengthening | Khavinson 2003; Al-dulaimi 2025 | Human cell culture | Yes (2025) |
| Extended replicative capacity | Khavinson 2004 | Human cell culture | Limited |
| Lifespan extension, fewer tumors | Anisimov 2003 | Rodent models | Sparse |
| Melatonin rhythm restoration | Korkushko 2007 | Aged monkeys / elderly humans | Limited |
| Subjective sleep improvement | Anecdotal / mechanistic | No controlled trials | None |
The honest summary: the mechanism is plausible and partly reproduced in vitro, the rodent longevity data are striking but concentrated in one research lineage, and the modern human clinical evidence is essentially absent. Much of the human material is older Russian work using the extract (epithalamin) rather than blinded trials of the synthetic tetrapeptide.
Reading a Cycle Table Critically
Because there is no gold-standard trial, every published epithalon dosing and cycle table is really an interpretation. When you see numbers, ask three things:
- Where did the dose come from? A round 10 mg figure usually reflects vial convenience, not a dose-response study.
- Is it epitalon or epithalamin? Much of the human data used the crude pineal extract, not the pure AEDG peptide.
- What is the endpoint? “Telomerase went up in a dish” is a very different claim from “people lived longer.”
If your interest is the broader longevity-peptide category, the mechanistic contrast with mitochondrial-targeted peptides is worth reading — see our overview of MOTS-c and SS-31 mitochondrial peptides, which sit on a completely different pathway from telomere maintenance.
The Cancer and Hormone-Sensitive Caution
This deserves its own line because it is the most important one. Telomerase reactivation is a double-edged mechanism: the same enzyme that maintains healthy-cell telomeres is also exploited by many cancers to become immortal. The 2025 replication study underscored this directly by showing epitalon lengthened telomeres in cancer cell lines (via the ALT pathway), not just normal cells. That does not prove epithalon causes cancer — but it is exactly why anyone with a current or past hormone-sensitive or malignant condition is flagged as a population where the risk/benefit is unresolved. There is no long-term human safety dataset to lean on here.
Frequently Asked Questions
What is the typical epithalon cycle and how often is it repeated?
The most-cited pattern is about 10 mg per day for 10 consecutive days (roughly a 100 mg course), repeated once or twice per year. This intermittent structure mirrors the short “course” dosing used in the original Russian bioregulator studies. It is a community convention, not a figure validated by a modern controlled human dose-ranging trial.
Does epithalon really lengthen telomeres or is the proof weak?
Both are true. Telomere lengthening via telomerase (hTERT) up-regulation is documented in human cell cultures, including a 2025 independent replication. But that is a dish, not a person — there are no robust modern human trials showing telomere lengthening translates to health or longevity benefits in living people. The mechanism is real; the human proof is weak.
What do people report feeling on epithalon — sleep, dreams, or nothing?
Anecdotally, the most common reports are deeper sleep and vivid dreams, consistent with the pineal-melatonin research showing restored nighttime melatonin peaks in aging subjects. Many others report no perceptible effect at all. Because no blinded sleep trials exist for epithalon specifically, these accounts remain subjective and unverified rather than clinically established.
Is epithalon a concern with cancer risk or hormone-sensitive conditions?
Potentially, yes — and it is taken seriously. Telomerase reactivation is a mechanism many cancers use to become immortal, and a 2025 study showed epitalon extended telomeres in cancer cell lines. That makes the risk/benefit unresolved for anyone with a current or prior hormone-sensitive or malignant condition, especially given the absence of long-term human safety data.
References
- Khavinson VKh, Bondarev IE, Butyugov AA. Epithalon peptide induces telomerase activity and telomere elongation in human somatic cells. Bulletin of Experimental Biology and Medicine. 2003;135(6):590-592.
- Khavinson VKh, Bondarev IE, Butyugov AA, Smirnova TD. Peptide promotes overcoming of the division limit in human somatic cell. Bulletin of Experimental Biology and Medicine. 2004;137(5):503-506.
- Anisimov VN, Khavinson VKh, Popovich IG, et al. Effect of Epitalon on biomarkers of aging, life span and spontaneous tumor incidence in female Swiss-derived SHR mice. Biogerontology. 2003;4(4):193-202.
- Korkushko OV, Khavinson VKh, Shatilo VB, Antonyuk-Shcheglova IA. Normalizing effect of the pineal gland peptides on the daily melatonin rhythm in old monkeys and elderly people. Advances in Gerontology. 2007;20(1):74-85.
- Anisimov VN, Khavinson VKh. Peptide bioregulation of aging: results and prospects. Biogerontology. 2010;11(2):139-149.
- Al-dulaimi S, Thomas R, Matta S, et al. Epitalon increases telomere length in human cell lines through telomerase upregulation or ALT activity. Biogerontology. 2025;26:178.
This article is provided for research and educational purposes only (research use only) and is not medical advice or a human-dosing recommendation.